Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Pfizer’s Precedex Up for PAFSC Review for Pediatric Indication as Japan’s 1st “Specific Use Drug” on Oct. 28
October 17, 2022
- Japan to Prepare Schedule for DX in Medical Fee Revisions by Next Spring
October 14, 2022
- Lawmakers Call for Starting 9-Valent HPV Vaccination Program in April 2023
October 14, 2022
- Contraindication Lifted for Parmodia in Renal Impairment Patients
October 14, 2022
- Japan Looks to Secure 950,000 Courses of Lagevrio by Year-End amid Twindemic Threat
October 14, 2022
- Govt Eyes Designation of Cefazolin, Other Antibiotics as Key Resources
October 14, 2022
- NHI-Market Price Gap at 20-Plus-Outlet Pharmacies 1.8 Times Larger vs. Small Hospitals
October 14, 2022
- Experts Urge MHLW to Present Detailed Data on Generic Manufacturing Costs
October 13, 2022
- Ways to Resolve Drug Lag/Loss, Fuel Development in Japan Up for Debate: MHLW Panel
October 13, 2022
- Panel Members Want More Data on Allocation of NHI-Market Price Margins
October 13, 2022
- MHLW Expert Panel Sorts Out Discussion Points for Full Debate; Focus on Innovation, Stable Supply, and Margins
October 13, 2022
- MHLW Asks Local Govts Not to Discard Near-Expired Pediatric COVID Jabs
October 12, 2022
- Japan to Roll Out BA.4/5 Omicron Boosters on Oct. 13, Inoculations for 6 Months to 4 Years from Oct. 24
October 11, 2022
- MHLW Panel to Discuss Shortening of COVID Booster Interval
October 11, 2022
- No Major Safety Concerns for COVID-19 Vaccines in Japan: Experts
October 11, 2022
- Japan Cabinet OKs Bill to Amend Infectious Disease Act, Other Laws
October 11, 2022
- AstraZeneca’s Evusheld Added to Updated MHLW COVID Guide
October 11, 2022
- Comirnaty Bags Special Approval in Japan for Kids Aged 6 Months to 4 Years
October 6, 2022
- Pfizer’s BA.4/5-Adapted Comirnaty Grabs Special Approval in Japan
October 6, 2022
- LDP Health Panel Chief Vows All-Round Support for Japan Drug Makers
October 6, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…